WO2010022145A3 - Alternatively-spliced isoform of mu-opioid receptor gene with cell excitatory function - Google Patents

Alternatively-spliced isoform of mu-opioid receptor gene with cell excitatory function Download PDF

Info

Publication number
WO2010022145A3
WO2010022145A3 PCT/US2009/054300 US2009054300W WO2010022145A3 WO 2010022145 A3 WO2010022145 A3 WO 2010022145A3 US 2009054300 W US2009054300 W US 2009054300W WO 2010022145 A3 WO2010022145 A3 WO 2010022145A3
Authority
WO
WIPO (PCT)
Prior art keywords
opioid receptor
mor
alternatively
receptor gene
novel
Prior art date
Application number
PCT/US2009/054300
Other languages
French (fr)
Other versions
WO2010022145A2 (en
Inventor
Luda Diatchenko
William Maixner
Pavel Gris
Josee Gauthier
Andrea Nackley
Original Assignee
The University Of North Carolina At Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of North Carolina At Chapel Hill filed Critical The University Of North Carolina At Chapel Hill
Publication of WO2010022145A2 publication Critical patent/WO2010022145A2/en
Publication of WO2010022145A3 publication Critical patent/WO2010022145A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways

Abstract

Splice variant forms of human OPRM1 and polynucleotide sequences encoding the OPRM1 splice variants are provided, including the novel sixtrans- membrane isoforms encoded by MOR-1 K1 and MOR-1 K2. Also provided are methods of screening compounds for their ability to regulate the activity of MOR-1 splice variants and of producing antibodies to the novel isoforms. Recombinant vectors, cells, and transgenic animals comprising the novel polypeptides or polynucleotides are described. Methods and assay kits for detecting the presence of a six transmembrane μ-opioid receptor isoform polypeptide are also provided.
PCT/US2009/054300 2008-08-19 2009-08-19 Alternatively-spliced isoform of mu-opioid receptor gene with cell excitatory function WO2010022145A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18943308P 2008-08-19 2008-08-19
US61/189,433 2008-08-19

Publications (2)

Publication Number Publication Date
WO2010022145A2 WO2010022145A2 (en) 2010-02-25
WO2010022145A3 true WO2010022145A3 (en) 2010-07-01

Family

ID=41707645

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/054300 WO2010022145A2 (en) 2008-08-19 2009-08-19 Alternatively-spliced isoform of mu-opioid receptor gene with cell excitatory function

Country Status (1)

Country Link
WO (1) WO2010022145A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096513A (en) * 1993-05-20 2000-08-01 Arch Development Corporation Polynucleotides encoding KAPPA opiod receptors
US6103492A (en) * 1993-03-08 2000-08-15 Indiana University Polynucleotide encoding mu opioid receptor
US6337207B1 (en) * 1998-07-10 2002-01-08 The Rockefeller University Alleles of the human mu opioid receptor, diagnostic methods using said alleles, and methods of treatment based thereon
WO2002068579A2 (en) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US20040096912A1 (en) * 2002-06-18 2004-05-20 Regents Of The University Of Minnesota Method to inhibit chronic pain
US7087714B2 (en) * 2001-06-29 2006-08-08 Memorial Sloan-Kettering Cancer Center Mu-Opiod receptor splice variant polypeptides

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103492A (en) * 1993-03-08 2000-08-15 Indiana University Polynucleotide encoding mu opioid receptor
US6096513A (en) * 1993-05-20 2000-08-01 Arch Development Corporation Polynucleotides encoding KAPPA opiod receptors
US6337207B1 (en) * 1998-07-10 2002-01-08 The Rockefeller University Alleles of the human mu opioid receptor, diagnostic methods using said alleles, and methods of treatment based thereon
WO2002068579A2 (en) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7087714B2 (en) * 2001-06-29 2006-08-08 Memorial Sloan-Kettering Cancer Center Mu-Opiod receptor splice variant polypeptides
US20040096912A1 (en) * 2002-06-18 2004-05-20 Regents Of The University Of Minnesota Method to inhibit chronic pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHAVALINA, S. ET AL., HUMAN MOLECULAR GENETICS, 22 December 2008 (2008-12-22) *

Also Published As

Publication number Publication date
WO2010022145A2 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
US11919930B2 (en) Odorant receptor co-receptor
IL180201A0 (en) Diagnostic and screening methods and kits associated with proteolytic activity
Devine et al. Miro sculpts mitochondrial dynamics in neuronal health and disease
Kaeser et al. ELKS2α/CAST deletion selectively increases neurotransmitter release at inhibitory synapses
WO2008145133A3 (en) Method for manufacturing a recombinant polyclonal protein
WO2009030237A3 (en) Methods for recombinant manufacturing of anti-rsv antibodies
MY160897A (en) Polypeptide having or assisting in carbohydrate material degrading activity and uses thereof
MX352265B (en) Neurotoxins exhibiting shortened biological activity.
RU2012132442A (en) ANTIBODY TO CD27
BRPI0821088A2 (en) nucleic acid construct, transgenic microbial host cell, and methods for producing a polypeptide having feruloyl esterase activity, for producing a mother cell mutant, for inhibiting expression of a polypeptide having feruloyl esterase activity in a cell, for produce a protein, and to degrade a xylan-containing material.
Hu et al. Piezo-like gene regulates locomotion in Drosophila larvae
EA201001881A1 (en) PROLINESCY PROTEZA FROM PENICILLIUM CHRYSOGENUM
Ming et al. Cellular reprogramming: recent advances in modeling neurological diseases
Mura et al. The KCNH2-IVS9-28A/G mutation causes aberrant isoform expression and hERG trafficking defect in cardiomyocytes derived from patients affected by Long QT Syndrome type 2
WO2009150222A3 (en) Improved protein expression system
Katoh et al. Comparative genomics on Wnt5a and Wnt5b genes
WO2010063818A3 (en) Methods for selecting protease resistant polypeptides
ES2780692T3 (en) Construct and Sequence for Enhanced Gene Expression
Gao et al. The transcription factor Pf‐POU 3F4 regulates expression of the matrix protein genes Aspein and Prismalin‐14 in pearl oyster (Pinctada fucata)
WO2009139919A3 (en) Methods for diagnosis of clostridium diffcile and methods and vectors for recombinant toxin expression
WO2010022145A3 (en) Alternatively-spliced isoform of mu-opioid receptor gene with cell excitatory function
WO2009014462A8 (en) Methods and polynucleotides for improving plants
RU2013104989A (en) DNA ELEMENT WITH ACTIVITY AIMED AT STRENGTHENING EXPRESSION OF AN ALIEN GENE
Katoh Molecular evolution of WNT2B orthologs
EA201300059A1 (en) POLYPEPTID, possessing the activity of the Volvolenin, and its application

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09808764

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09808764

Country of ref document: EP

Kind code of ref document: A2